Publication | Closed Access

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Surgical OncologyBone Sarcoma GroupGastrointestinal OncologyMedicinePathologyCancer GenomicsEortc Soft TissueC-kit/pdgfra Mutational AnalysisCancer GeneticsOncologyRadiation Oncology